First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation

被引：7
|
作者：
De, Surya K. [1 ,2 ]
机构：
[1] Conju Probe, Dept Chem, San Diego, CA 92121 USA
[2] Bharath Univ, Chennai 600126, Tamil Nadu, India
来源：
CURRENT MEDICINAL CHEMISTRY | 2024年 / 31卷 / 03期
关键词：
Non-small cell lung cancer; KRAS mutation; guanosine triphosphate; guanosine diphosphate; adagrasib; sotorasib; RESISTANCE; RAS;
D O I：
10.2174/0929867330666230330122000
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Adagrasib is an orally bioavailable, highly selective, small-molecule, irreversible covalent inhibitor of KRAS(G12C). It was approved by the US FDA on December 12, 2022, for patients with tumors harboring the KRAS(G12C )mutation in locally advanced or metastatic non-small cell lung cancer (NSCLC). Herein, synthesis, dosage and administration, mechanism of action, pharmacokinetics, pharmacodynamics, and adverse events of adagrasib are described.
引用
收藏
页码：266 / 272
页数：7
相关论文
共 50 条
  • [31] Adagrasib: a novel inhibitor for KRASG12C-mutated non-small-cell lung cancer
    Guo, Matthew Z.
    Marrone, Kristen A.
    Spira, Alexander
    Rosner, Samuel
    FUTURE ONCOLOGY, 2023, 19 (15) : 1037 - 1051
  • [32] Synergistic enhancement of KRASG12C inhibitor adagrasib by AMD1 inhibitor SAM486 in non-small cell lung cancer: in vitro and in vivo studies
    Lopez-Munoz, R.
    Martin-Martin, A.
    Buelvas, N.
    Guzman-Kunstmann, S.
    Chipon, C.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S87 - S87
  • [33] KRASG12C Inhibitor as a Treatment Option for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia
    Fujimoto, Kazushi
    Ikeda, Satoshi
    Tabata, Erina
    Kaneko, Taichi
    Sagawa, Shinobu
    Yamada, Chieri
    Kumagai, Kosumi
    Fukushima, Takashi
    Haga, Sanshiro
    Watanabe, Masayuki
    Muraoka, Tatsuya
    Sekine, Akimasa
    Baba, Tomohisa
    Ogura, Takashi
    CANCERS, 2024, 16 (07)
  • [34] First-in-Humans PET Imaging of KRASG12C Mutation Status in Non-Small Cell Lung and Colorectal Cancer Patients Using [18F]PFPMD
    Li, Xiang
    Ye, Jiajun
    Wang, Jingyi
    Quan, Zhiyong
    Li, Guiyu
    Ma, Wenhui
    Zhang, Mingru
    Yang, Weidong
    Wang, Junling
    Ma, Taoqi
    Kang, Fei
    Wang, Jing
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (12) : 1880 - 1888
  • [35] Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
    Torres-Jimenez, Javier
    Espinar, Javier Baena
    de Cabo, Helena Bote
    Berjaga, Maria Zurera
    Esteban-Villarrubia, Jorge
    Fraile, Jon Zugazagoitia
    Paz-Ares, Luis
    DRUGS, 2024, 84 (05) : 527 - 548
  • [36] Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRASG12C Inhibitor, in Patients with Non-Small Cell Lung Cancer
    Govindan, R.
    Fakih, M.
    Price, T.
    Falchook, G.
    Desai, J.
    Kuo, J.
    Strickler, J.
    Krauss, J.
    Li, B.
    Denlinger, C.
    Durm, G.
    Ngang, J.
    Henary, H.
    Ngarmchamnanrith, G.
    Rasmussen, E.
    Morrow, P. K.
    Hong, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1125 - S1126
  • [37] Use of adagrasib in advanced solid tumors harboring the KRASG12C mutation-commentary on the KRYSTAL-1 study
    Plum, Patrick Sven
    Alakus, Hakan
    Gockel, Ines
    ONKOLOGIE, 2023, 29 (09): : 814 - 816
  • [38] Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib
    Zhang, Jun
    Johnson, Melissa
    Barve, Minal
    Bazhenova, Lyudmila
    McCarthy, Marybeth
    Schwartz, Rowena
    Horvath-Walsh, Elise
    Velastegui, Karen
    Qian, Chunlin
    Spira, Alexander
    ONCOLOGIST, 2023, : 287 - 296
  • [39] Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models
    Sisler, Daniel J.
    Hinz, Trista K.
    Le, Anh T.
    Kleczko, Emily K.
    Nemenoff, Raphael A.
    Heasley, Lynn E.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [40] Impact of trial eligibility criteria on enrollment to KRASG12C inhibitor trials in patients with non-small cell lung cancer.
    May, Michael S.
    Wooster, Margaux
    May, Benjamin
    Shu, Catherine A.
    Henick, Brian S.
    Stoopler, Mark
    Smith-Marrone, Stephanie
    Saqi, Anjali
    Mansukhani, Mahesh M.
    Riely, Gregory J.
    Hershman, Dawn L.
    Herzberg, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345